- Home
- MCRB vs DIT Comparison
MCRB vs DIT Comparison
Compare MCRB & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- DIT
- Stock Information
- Founded
- MCRB 2010
- DIT 1981
- Country
- MCRB United States
- DIT United States
- Employees
- MCRB N/A
- DIT N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- DIT Food Distributors
- Sector
- MCRB Health Care
- DIT Consumer Discretionary
- Exchange
- MCRB Nasdaq
- DIT Nasdaq
- Market Cap
- MCRB 72.0M
- DIT 78.7M
- IPO Year
- MCRB 2015
- DIT 1995
- Fundamental
- Price
- MCRB $7.63
- DIT $106.90
- Analyst Decision
- MCRB Hold
- DIT
- Analyst Count
- MCRB 4
- DIT 0
- Target Price
- MCRB $73.67
- DIT N/A
- AVG Volume (30 Days)
- MCRB 75.0K
- DIT 308.0
- Earning Date
- MCRB 08-12-2025
- DIT 07-17-2025
- Dividend Yield
- MCRB N/A
- DIT 0.71%
- EPS Growth
- MCRB N/A
- DIT N/A
- EPS
- MCRB 8.98
- DIT 2.44
- Revenue
- MCRB N/A
- DIT $2,221,421,072.00
- Revenue This Year
- MCRB N/A
- DIT N/A
- Revenue Next Year
- MCRB N/A
- DIT N/A
- P/E Ratio
- MCRB $0.89
- DIT $41.84
- Revenue Growth
- MCRB N/A
- DIT 7.47
- 52 Week Low
- MCRB $6.53
- DIT $94.92
- 52 Week High
- MCRB $30.60
- DIT $166.00
- Technical
- Relative Strength Index (RSI)
- MCRB 48.66
- DIT 48.13
- Support Level
- MCRB $7.25
- DIT $94.92
- Resistance Level
- MCRB $7.89
- DIT $107.00
- Average True Range (ATR)
- MCRB 0.46
- DIT 4.16
- MACD
- MCRB 0.11
- DIT 0.25
- Stochastic Oscillator
- MCRB 60.23
- DIT 72.30
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About DIT AMCON Distributing Company
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores, and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.